Durability of partial splenic artery embolization on platelet counts for cancer patients with hypersplenism-related thrombocytopenia.

摘要: Purpose Partial splenic artery embolization (PSAE) has shown promise in increasing platelet counts cancer patients with hypersplenism-related thrombocytopenia. The purpose of this study was to identify response predictors and longitudinally evaluate PSAE efficacy durability a large cohort Methods A single-institution, IRB-approved, HIPAA-compliant retrospective review all PSAEs for thrombocytopenia between 2012 2015 performed. Patients were classified as complete responders (CR, no value 100 × 109/L following PSAE). Results Of the 98 included study, 58 had CR (59%), 28 PR (29%), 12 NR (12%). percent tissue embolized significantly greater group compared (P = 0.001). volume linearly correlated magnitude increase without minimum threshold. At least one line chemotherapy successfully restarted 97% patients, 41% did not experience recurrence duration their survival. major complication rate 8%, readmission initial hospitalization persistent "post-embolization syndrome" symptoms most common. Conclusions In thrombocytopenia, is safe intervention that effects durable elevation across range malignancies re-initiation chemotherapy.